Dow Down0.97% Nasdaq Down1.17%

Anika Therapeutics Inc. (ANIK)

-NasdaqGS
44.97 Down 0.60(1.32%) 12:26PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Anika Therapeutics Inc.
32 Wiggins Avenue
Bedford, MA 01730
United States - Map
Phone: 781-457-9000
Fax: 781-305-9720
Website: http://www.anikatherapeutics.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:N/A

Business Summary 

Anika Therapeutics, Inc., together with its subsidiaries, provides therapeutic pain management solutions for patients with degenerative orthopedic diseases and traumatic conditions in the United States, Canada, Europe, and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise Hyalomatrix and Hyalofill for treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise Hyalobarrier, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product for the prevention of spinal post-surgical adhesions; Merogel, a woven fleece nasal packing; and Merogel Injectable, a viscous hydrogel. The company’s ophthalmic products include STAARVISC-II, Optivisc, AnikaVisc, and NUVISC that are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, including cataract extraction and intraocular lens implantation. Its veterinary product comprise HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Anika Therapeutics Inc.

Corporate Governance 
Anika Therapeutics Inc.’s ISS Governance QuickScore as of May 1, 2016 is 10. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 10; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Charles H. Sherwood Ph.D., 69
Chief Exec. Officer, Pres and Director
1.14M1.54M
Ms. Sylvia Cheung , 41
Chief Financial Officer, Sec. and Treasurer
542.00K119.00K
Dr. Edward S. Ahn Ph.D., 44
Chief Technology & Strategy Officer
460.00KN/A
Mr. Richard Hague , 56
Chief Commercial Officer
73.00KN/A
Mr. Frank J. Luppino , 48
Consultant
316.00K5.34M
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders